Gilead Sciences : GILD

All Gilead Sciences Articles

732 Articles

Lee Jackson | Oct 26, 2018 at 9:15 AM EDT

Top Analyst Upgrades and Downgrades: GoldCorp, Gilead, GrubHub, Hilton Worldwide, KKR, Raymond James, Western Digital and More

The top analyst upgrades, downgrades and other research calls from Friday included GoldCorp, Gilead, GrubHub, Hilton Worldwide, KKR, Raymond James…

Chris Lange | Oct 25, 2018 at 8:20 AM EDT

Short Sellers Hike Their Bets in Major Biotechs

The October 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Oct 21, 2018 at 10:15 AM EDT

Top Biotech Earnings Reports to Watch This Week

Here is a preview of some of the world’s largest players in the health care sector reporting earnings this coming…

Chris Lange | Oct 10, 2018 at 8:20 AM EDT

Short Sellers Back Off Major Biotechs

The September 28 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Sep 26, 2018 at 8:15 AM EDT

Major Biotechs Have Short Sellers on the Run

The September 14 short interest data have been compared with the previous report, and short interest in most of the…

Jon C. Ogg | Sep 24, 2018 at 10:45 AM EDT

What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies…

Lee Jackson | Sep 24, 2018 at 10:25 AM EDT

Jefferies Biotech Growth Picks Have Big Upside Potential

Jefferies highlights the firm's top growth stocks to buy each week, and recently four top biotech stocks made the cut.…

Chris Lange | Sep 13, 2018 at 8:20 AM EDT

Short Sellers Up the Ante in Major Biotechs

24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The August 31 short interest data…

Chris Lange | Sep 12, 2018 at 9:55 AM EDT

Why Gilead Is Banking Big on Hepatitis B and Rheumatoid Arthritis

Gilead shares were up handily on Wednesday after the company announced that it had entered into a strategic collaboration with…

Jon C. Ogg | Aug 28, 2018 at 1:45 PM EDT

Are Some Cancer Treatments Becoming Too Expensive to Approve?

The topic of acceptable costs versus acceptable results is one that may never have a final conclusion in which everyone…

Chris Lange | Aug 27, 2018 at 7:05 AM EDT

Short Sellers Run for Cover From Major Biotechs

The August 15 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Aug 10, 2018 at 8:45 AM EDT

Why Have Short Sellers Backed Off Major Biotechs?

The July 31 short interest data have been compared with the previous report, and short interest in most of the…

Lee Jackson | Jul 26, 2018 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: Dolby Labs, Facebook, Freeport-McMoRan, Gilead, GrubHub, Skechers and More

The top analyst upgrades, downgrades and other research calls from Thursday include Dolby Laboratories, Facebook, Freeport-McMoRan, Gilead, GrubHub and Skechers.

Chris Lange | Jul 25, 2018 at 4:19 PM EDT

Gilead Earnings Beat Not Enough For Investors

Gilead reported its most recent quarterly results after the markets closed on Wednesday. The major biotech posted $1.91 in earnings…

Chris Lange | Jul 25, 2018 at 12:40 PM EDT

What to Expect When Gilead Reports

Gilead is scheduled to release its second-quarter financial results after the markets close on Wednesday, and analyst expectations are low.

1 … 14 15 16 17 18 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Top Analyst Upgrades and Downgrades: GoldCorp, Gilead, GrubHub, Hilton Worldwide, KKR, Raymond James, Western Digital and More

Short Sellers Hike Their Bets in Major Biotechs

Top Biotech Earnings Reports to Watch This Week

Short Sellers Back Off Major Biotechs

Major Biotechs Have Short Sellers on the Run

What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

Jefferies Biotech Growth Picks Have Big Upside Potential

Short Sellers Up the Ante in Major Biotechs

Why Gilead Is Banking Big on Hepatitis B and Rheumatoid Arthritis

Are Some Cancer Treatments Becoming Too Expensive to Approve?

Short Sellers Run for Cover From Major Biotechs

Why Have Short Sellers Backed Off Major Biotechs?

Top Analyst Upgrades and Downgrades: Dolby Labs, Facebook, Freeport-McMoRan, Gilead, GrubHub, Skechers and More

Gilead Earnings Beat Not Enough For Investors

What to Expect When Gilead Reports

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

Gilead Sciences : GILD

All Gilead Sciences Articles

Top Analyst Upgrades and Downgrades: GoldCorp, Gilead, GrubHub, Hilton Worldwide, KKR, Raymond James, Western Digital and More

Short Sellers Hike Their Bets in Major Biotechs

Top Biotech Earnings Reports to Watch This Week

Short Sellers Back Off Major Biotechs

Major Biotechs Have Short Sellers on the Run

What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

Jefferies Biotech Growth Picks Have Big Upside Potential

Short Sellers Up the Ante in Major Biotechs

Why Gilead Is Banking Big on Hepatitis B and Rheumatoid Arthritis

Are Some Cancer Treatments Becoming Too Expensive to Approve?

Short Sellers Run for Cover From Major Biotechs

Why Have Short Sellers Backed Off Major Biotechs?

Top Analyst Upgrades and Downgrades: Dolby Labs, Facebook, Freeport-McMoRan, Gilead, GrubHub, Skechers and More

Gilead Earnings Beat Not Enough For Investors

What to Expect When Gilead Reports

‘You’re Gonna Go Into Retirement Broke and Wait on Mom to Die’: Dave Ramsey’s Reality Check for a Caller Eyeing His Inheritance

“You Don’t Want to Pass the Burden of Investments Down to Your Daughter”: Suze Orman’s Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings

EEM’s 0.69% Fee Quietly Costs You $690 a Year, but Your Cheaper Alternative Charges $90

Featured Reads

'You're Gonna Go Into Retirement Broke and Wait on Mom to Die': Dave Ramsey's Reality Check for a Caller Eyeing His Inheritance

"You Don't Want to Pass the Burden of Investments Down to Your Daughter": Suze Orman's Advice to a 78-Year-Old With a Disabled Heir and $111K in Savings